Gilead Reports Presented New Data On Biktarvy, TAF-Based Regimens For Treatment Of HIV-1: Through Week 48, Biktarvy Maintained High Rates Of Virologic Suppression With Low Incidence Of Study Drug-Related Adverse Events,